Related Experiment Videos
Self-replicating Semliki Forest virus RNA as recombinant vaccine
1Center for Biotechnology, Karolinska Institute, Huddinge, Sweden.
Vaccine
|December 1, 1994
Summary
Recombinant RNA vaccines based on Semliki Forest virus (SFV) effectively express influenza nucleoprotein in mice. Both direct RNA injection and SFV particle delivery generated strong antibody and T-cell responses, indicating potential as nucleic acid vaccines.
Area of Science:
- Virology
- Vaccinology
- Molecular Biology
Background:
- The Semliki Forest virus (SFV) replicon system offers a platform for expressing foreign antigens.
- Developing effective nucleic acid vaccines is a key goal in modern vaccinology.
Purpose of the Study:
- To evaluate the immunogenicity of recombinant RNA-based vaccines expressing influenza virus nucleoprotein in mice.
- To compare two distinct RNA delivery strategies for vaccine development.
Main Methods:
- Utilized recombinant RNA based on the SFV replicon to express influenza nucleoprotein.
- Employed two delivery methods: packaging RNA into infectious suicide SFV particles and direct injection of in vitro-synthesized RNA into muscle tissue.
- Assessed humoral immune responses (antibody titres) and cell-mediated immunity (cytotoxic T-cell responses).
Main Results:
- Both delivery strategies successfully generated humoral immune responses with high antibody titres.
- Immunization with suicide SFV particles induced a potent, class I-restricted cytotoxic T-cell response, even at low doses (100 infectious units).
Conclusions:
- Self-replicative recombinant SFV RNA is a promising candidate for nucleic acid vaccine development.
- The SFV replicon system provides an effective platform for inducing both humoral and cellular immunity against viral antigens.